Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current revenue (TTM ) is โฌ40.30 Billion. In 2024 the company made a revenue of โฌ40.22 Billion an increase over the revenue in the year 2023 that were of โฌ30.54 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.